Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 3—March 2018
Research

Epidemiology and Molecular Identification and Characterization of Mycoplasma pneumoniae, South Africa, 2012–2015

Maimuna CarrimComments to Author , Nicole Wolter, Alvaro J. Benitez, Stefano Tempia, Mignon du Plessis, Sibongile Walaza, Fahima Moosa, Maureen H. Diaz, Bernard J. Wolff, Florette K. Treurnicht, Orienka Hellferscee, Halima Dawood, Ebrahim Variava, Cheryl Cohen, Jonas M. Winchell, and Anne von Gottberg
Author affiliations: National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa (M. Carrim, N. Wolter, S. Tempia, M. du Plessis, S. Walaza, F. Moosa, F.K. Treurnicht, O. Hellferscee, C. Cohen, A. von Gottberg); University of the Witwatersrand, Johannesburg (N. Wolter, M. du Plessis, S. Walaza, E. Variava, C. Cohen, A. von Gottberg); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A.J. Benitez, S. Tempia, M.H. Diaz, B.J. Wolff, J.M. Winchell); Pietermaritzburg Metropolitan Hospitals, Pietermaritzburg, South Africa (H. Dawood); Centre for the AIDS Programme of Research in South Africa, Pietermaritzburg (H. Dawood); University of KwaZulu-Natal, Pietermaritzburg (H. Dawood); Klerksdorp-Tshepong Hospital Complex, Klerksdorp, South Africa (E. Variava); Perinatal HIV Research Unit, Johannesburg (E. Variava)

Main Article

Table 3

Incidence of hospitalization for Mycoplasma pneumoniae, by age group and HIV status, Klerksdorp and Pietermaritzburg, South Africa, January 2013–December 2014*

Age group, y
 No. cases/100,000 population (95% CI) Risk ratio (95% CI), HIV infected vs. uninfected
All patients
 HIV-infected patients
 HIV-uninfected patients
<1 220.0 (121.0–314.8) 594.8 (316.4–873.2) 216.7 (128.3–303.8) 2.8 (0.4–18.6)
1–4 53.9 (30.1–75.6) 961.7 (518.4–1391.6) 35.9 (21.1–50.2) 26.8 (14.4–49.8)
5–24 14.1 (9.4–18.6) 130.0 (81.1–173.8) 5.5 (3.9–7.1) 23.8 (13.4–42.4)
25–44 21.4 (15.0–27.6) 70.1 (46.3–95.1) 0 (0–46.7) NA
45–64 26.2 (17.6–34.9) 118.7 (81.2–159.3) 4.7 (3.4–6.2) 25.6 (9.9–65.9)
>65
 56.2 (37.5–74.2)
 0 (0–234.1)
 57.8 (41.3–74.9)
 NA
<5 87.1 (60.2–114.0) 927.3 (621.3–1231.5) 72.3 (50.5–93.8) 16.1 (9.4–27.6)†
>5
 20.5 (14.0–26.9)
 91.3 (59.0–122.4)
 6.3 (4.5–8.4)
 21.6 (14.8–31.7)†
All 27.9 (18.9–37.4) 102.2 (64.9–136.4) 14.9 (10.3–19.0) 19.5 (14.4–26.4)†

*NA, not applicable.
†Adjusted for age.

Main Article

Page created: February 15, 2018
Page updated: February 15, 2018
Page reviewed: February 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external